Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy
- PMID: 24738700
- DOI: 10.1111/jns5.12059
Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy
Abstract
The Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) questionnaire is an instrument to assess QOL in diabetic polyneuropathy. The objective of this observational, cross-sectional study in 61 patients with V30M transthyretin familial amyloid polyneuropathy (TTR-FAP) and 16 healthy volunteers was to validate the Norfolk QOL-DN for assessment of QOL in TTR-FAP. Comparisons were conducted to identify the best items to discriminate disease stages and assess which individual Norfolk domains (symptoms, large fiber, small fiber, autonomic, and activities of daily living) would be most affected by disease stage. Analysis of individual items revealed a significant pattern of discrimination among disease stages (p < 0.001). Total QOL scores increased (indicating worsening) with duration of symptoms, with a steeper increase observed earlier in the course of disease. Significant correlations were observed between each Norfolk domain and other measures of neurological function. Limitations include cross-sectional study design, low patient numbers in this rare disease, and the ordinal-based character of the metric used; future areas to explore include item response theory approaches such as Rasch analysis. These results suggest the Norfolk QOL-DN is a reliable indicator of the impact of disease severity on QOL in patients with TTR-FAP.
Keywords: Norfolk quality of life; nerve-fiber function; neurological function; outcome measure; transthyretin amyloid polyneuropathy.
© 2014 Peripheral Nerve Society.
Similar articles
-
Clinical measures in transthyretin familial amyloid polyneuropathy.Muscle Nerve. 2017 Mar;55(3):323-332. doi: 10.1002/mus.25257. Epub 2016 Dec 16. Muscle Nerve. 2017. PMID: 27422379
-
The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy.Diabetes Technol Ther. 2005 Jun;7(3):497-508. doi: 10.1089/dia.2005.7.497. Diabetes Technol Ther. 2005. PMID: 15929681
-
The Val30Met familial amyloid polyneuropathy specific Rasch-built overall disability scale (FAP-RODS(©) ).J Peripher Nerv Syst. 2015 Sep;20(3):319-27. doi: 10.1111/jns.12120. J Peripher Nerv Syst. 2015. PMID: 26115039
-
"Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy.J Peripher Nerv Syst. 2016 Mar;21(1):5-9. doi: 10.1111/jns.12153. J Peripher Nerv Syst. 2016. PMID: 26663427 Free PMC article. Review.
-
Familial amyloid polyneuropathy.Lancet Neurol. 2011 Dec;10(12):1086-97. doi: 10.1016/S1474-4422(11)70246-0. Lancet Neurol. 2011. PMID: 22094129 Review.
Cited by
-
Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis.J Neurol. 2020 Apr;267(4):1070-1079. doi: 10.1007/s00415-019-09671-9. Epub 2019 Dec 18. J Neurol. 2020. PMID: 31853709 Free PMC article. Clinical Trial.
-
Responder analysis for neuropathic impairment and quality-of-life assessment in patients with hereditary transthyretin amyloidosis with polyneuropathy in the NEURO-TTR study.J Neurol. 2022 Jan;269(1):323-335. doi: 10.1007/s00415-021-10635-1. Epub 2021 Jun 14. J Neurol. 2022. PMID: 34125267 Free PMC article.
-
Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy.Neurol Ther. 2023 Oct;12(5):1759-1775. doi: 10.1007/s40120-023-00522-4. Epub 2023 Jul 31. Neurol Ther. 2023. PMID: 37523143 Free PMC article.
-
Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis.Front Cardiovasc Med. 2023 Mar 14;10:1124660. doi: 10.3389/fcvm.2023.1124660. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 36998975 Free PMC article.
-
Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health-Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin Amyloidosis.Muscle Nerve. 2025 Jan;71(1):96-107. doi: 10.1002/mus.28299. Epub 2024 Nov 17. Muscle Nerve. 2025. PMID: 39552102 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous